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Identification of Poly (ADP-ribose) Polymerase-1 (PARP-1) as a
Novel Krüppel-like Factor 8-interacting and -regulating Protein*□
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Heng Lu‡, Xianhui Wang‡1, Tianshu Li‡, Alison M. Urvalek‡2, Lin Yu‡, Jieli Li§, Jinghua Zhu¶, Qishan Lin¶, Xu Peng§,
and Jihe Zhao‡3
From the ‡Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, Florida 32827, the
¶
Center for Functional Genomics, University at Albany, Rensselaer, New York 12144, and the §Department of Systems Biology and
Translational Medicine, College of Medicine, Texas A&M Health Science Center, Temple, Texas 76504-7105
Krüppel-like factor 8 (KLF8) regulates critical gene transcription and cellular events associated with cancer. However, KLF8interacting proteins remain largely unidentified. Using co-immunoprecipitation (co-IP), mass spectrometry, and GST pulldown
assays, we identified poly(ADP-ribose) polymerase-1 (PARP-1) as a
novel KLF8-interacting protein. Co-IP and Western blotting indicated that KLF8 is also a PARP-1 substrate. Mutation of the cysteines in the zinc finger domain of KLF8 abolished PARP-1 interaction. Surprisingly, immunofluorescent staining revealed a
cytoplasmic mislocalization of KLF8 in PARP-1ⴚ/ⴚ cells or when
the interaction was disrupted. This mislocalization was prevented
by either PARP-1 re-expression or inhibition of CRM1-dependent
nuclear export. Interestingly, co-IP indicated competition between
PARP-1 and CRM1 for KLF8 binding. Cycloheximide chase assay
showed a decrease in the half-life of KLF8 protein when PARP-1
expression was suppressed or KLF8-PARP-1 interaction was disrupted. Ubiquitination assays implicated KLF8 as a target of ubiquitination that was significantly higher in PARP-1ⴚ/ⴚ cells. Promoter reporter assays and chromatin immunoprecipitation assays
showed that KLF8 activation on the cyclin D1 promoter was markedly reduced when PARP-1 was deleted or inhibited or when
KLF8-PARP-1 interaction was disrupted. Overall, this work has
identified PARP-1 as a novel KLF8-binding and -regulating protein
and provided new insights into the mechanisms underlying the
regulation of KLF8 nuclear localization, stability, and functions.

KLF8 is a Krüppel-like transcription factor (KLF)4 family
member that plays a critical role in the regulation of important
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cellular processes including cell cycle progression (1– 4), oncogenic transformation (5), epithelial-to-mesenchymal transition, migration, and invasion (6). The transcription of KLF8 is
regulated by cell signaling molecules such as Src and PI3K
downstream of focal adhesion kinase (1, 7) and transcriptional
activators such as Sp1 (2), KLF1, and KLF3 (8). The cellular
function of KLF8 is regulated by post-translational sumoylation
(3) and acetylation (9). As a typical KLF family member, KLF8
contains three highly conserved C2H2 zinc fingers on the C
terminus, which can bind to the GT-box (CACCC) promoter
sequence (10). KLF8 binds directly to the cyclin D1 promoter
and activates the transcription (1) by recruiting the p300 and
p300/CBP-associated factor transcription co-activators (11).
KLF8 also functions as a transcriptional repressor on the
promoters of ␥-globin (10), KLF4 (3), and E-cadherin (6).
Two nuclear localization signals on KLF8 were identified
within the activation domain and the zinc finger domain,
respectively (4, 11).
Poly(ADP-ribose) polymerase-1 (PARP-1), the founding
member of the PARP enzyme family, is a nuclear enzyme
responsible for post-translational modification poly(ADP-ribosyl)ation (or PARylation). It has been implicated in the regulation of a wide range of important cellular processes including
chromatin organization, transcription, DNA repair, genomic
integrity, differentiation, proliferation, cell death, and cancer
progression (12–14). Pharmacologic inhibition of PARP-1 has
shown a strong antitumor effect in preclinical and clinical trials
(12, 15–18).
Significant progress has been made in the understanding of
KLF8-regulated cellular events and target genes. However, its
interacting proteins have been understudied. In this study, we
performed mass spectrometric screening of KLF8-binding proteins and identified PARP-1 as a novel interacting and regulating protein of KLF8. We present evidence showing that interaction and PARylation of KLF8 by PARP-1 are critical for
maintaining the proper subcellular localization, transcriptionregulating function, and protein stability of KLF8 in the
nucleus.

EXPERIMENTAL PROCEDURES
Antibodies and Reagents—The anti-HA antibody (F-7), antiMyc antibody (9E10), and anti-PARP-1 antibody (sc-25780)
were purchased from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA). Anti-HA and anti-Myc antibody-conjugated agarose beads, leptomycin B (LMB), and PJ-34 were purchased
JOURNAL OF BIOLOGICAL CHEMISTRY
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from Sigma. Anti-PAR antibody was purchased from Travigen,
Inc. (Gaithersburg, MD). IgG was purchased from Jackson
ImmunoResearch Laboratories (West Grove, PA). Nicotinamide was purchased from Acros Organics (NJ). Cycloheximide
and doxorubicin were purchased from Calbiochem.
Plasmid Construction—The mammalian expression plasmids pKH3, pKH3-KLF8, pHAN, and pHAN-KLF8 were previously described (1, 3). All the KLF8 mutants were generated by
site-directed mutagenesis PCR or overlapping PCR using
pKH3-KLF8 or pHAN-KLF8 as the template and mutationspecific primers paired with one of the master primers
(forward, 5⬘-CCCAAGCTTCTGCAGGTCG-3⬘, and reverse, 5⬘-GGACAAACCACAACTAGAATGCAG-3⬘). dN100,
dN200, dC26, dC38, dC56, dC82, H294/8L, H324/8L, mZF1dC,
mZF2dC, dZF1, and dZF2 mutants were previously described
(4). The primer pairs forward and reverse used to generate the
rest of the KLF8 point mutants are as follows: C276A, 5⬘-tgc aaa
gtc agc ttg gtg aat c-3⬘ and 5⬘-ttc acc aag ctg act ttg c-3⬘; C281A,
5⬘-act ttg ctg gct cct gca aag tc-3⬘ and 5⬘-ttg cag gag cca gca
aag-3⬘; C306A, 5⬘-tcc cag gtg gct tta taa ggc-3⬘ and 5⬘-agc ctt ata
aag cca cct ggg-3⬘; C311A, 5⬘-tcc agg agg cgc cat ccc-3⬘ and
5⬘-tgg gat ggc gcc tcc tgg-3⬘. ZF1mCs is the double mutant of
C276A and C281A. ZF2mCs is the double mutant of C306A
and C311A. ZF1,2mCs is the double mutant of ZF1mCs and
ZF2mCs. Human PARP-1 expression vector was kindly provided by Dr. Zhao-qi Wang (Leibniz Institute For Age
Research–Fritz Lipmann Institute, Jena, Germany) (19). MycPARP-1 was generated by cloning PARP-1 into the pHAN vector using the primers forward and reverse: 5⬘-agt aga tct gcg gag
tct tc-3⬘ and 5⬘-act ccc ggg tta cca cag g-3⬘. Myc-E988K
(PARP-1 mutant lacking poly(ADP-ribosylation)) was generated by PCR-directed mutagenesis using the primers (forward/
reverse): 5⬘-atc gat atc ttt aag ata g/atg tac ttg tta tat ag-3⬘.
Cell Culture and Transfection—HEK293T and MCF10A
cells were purchased from the American Type Culture Collection. T80, the immortalized human ovarian epithelial cell line,
was kindly provided by Dr. Jinsong Liu (20). PARP-1⫺/⫺ and
PARP-1⫹/⫹ mouse embryonic fibroblast (MEF) cells were kind
gifts from Dr. Zhao-qi Wang (19). Primary MEFs were isolated
as described previously (21, 22) and kindly provided by Dr.
Hamid Boulares of Louisiana State University. HEK293T, T80,
and MEF cells were maintained in DMEM supplemented with
10% fetal bovine serum (Mediatech) and 100 units/ml penicillin-streptomycin (Invitrogen). MCF10A cells were cultured as
described previously (6). Transfections of the plasmid DNAs
were performed using Lipofectamine2000 (Invitrogen) according to the manufacturer’s instructions.
Parallel Affinity Precipitation and Mass Spectrometry—
HEK293T cells were transfected with pKH3-KLF8, pHANKLF8, or one of the control vectors for 24 h. The transfected
cells from 100-mm dishes were lysed with Nonidet P-40 buffer
supplemented with protease inhibitors (1 mM Na3VO4, 1 mM
PMSF, 20 g/ml leupeptin, and 0.06 trypsin inhibitor unit/ml
aprotinin). Precleared cell lysates were incubated with antiHA- or anti-Myc-conjugated beads for 24 h in a cold room. The
immunoprecipitates were washed three times, eluted with SDS
sample buffer, resolved on an SDS-PAGE gel, and stained with
the Bio-SafeTM Coomassie Blue stain solution (Bio-Rad). In
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addition to the HA-KLF8 and Myc-KLF8 bands, protein bands
common to HA-KLF8- and Myc-KLF8-expressing cells but
missing from the control cells were excised from the gel. The gel
pieces were then washed, reduced, alkylated, and in-gel tryptic
or chymotryptic digested. Proteolytic peptides were extracted
from the gel, and peptides were concentrated and reconstituted
in 10 l of 5% formic acid followed by 5% liquid chromatography tandem mass spectrometry analysis using a Waters ESI
Q-TOF2 system. In-house MASCOT 2.2 from Matrix Science
(London, UK) was used to assist in the interpretation of tandem
mass spectra.
Promoter Reporter Assays—Luciferase reporter assays were
performed essentially as described previously (1, 2). Briefly,
cells were plated to ⬃60% confluency in a 12-well plate. The
⫺962-bp cyclin D1 promoter-luciferase reporter construct (0.2
g) and 4 ng of pRISV40 Renilla luciferase reporter vector were
co-transfected into PARP-1⫺/⫺ or PARP-1⫹/⫹ cells with 0.2 g
of the expression vectors encoding KLF8 or KLF8 mutants with
or without 1.0 g of PARP-1, E988K, or control vector. In some
experiments, 24-h transfected cells were treated with 3 M
PJ-34 or 10 mM nicotinamide for 12 h.
Fluorescent Microscopy—PARP-1⫺/⫺ and PARP-1⫹/⫹ cells
were transfected or co-transfected with KLF8, KLF8-mut,
PARP-1, or E988K for 24 h and processed for indirect immunofluorescence staining as described (23). Briefly, the primary
antibodies used were anti-HA (Y-11) and/or anti-Myc (9E10)
antibodies (1:200). The secondary antibodies used were FITCconjugated goat-anti rabbit antibody and/or Texas Red-conjugated goat-anti mouse (1:200, Jackson ImmunoResearch Laboratory, West Grove, PA). The nuclei were stained with Hoechst
33258 dye. Images were acquired with an Olympus BMX-60
microscope equipped with a cooled charge-coupled device
sensi-camera (Cooke, Auburn Hills, MI) and Slidebook software (Intelligent Imaging Innovations, Denver, CO). At least
200 positively transfected cells were examined for each of multiple experiments.
RNA Interference—PARP-1 and GFP ON-TARGETplus
siRNAs from Dharmacon (J006656-05, 5⬘-GAU UUC AUC
UGG UGU GAU A-3⬘; J006656-06, 5⬘-GAA AAC AGG UAU
UGG AUA U-3⬘; J006656-07, 5⬘-GUU CUU AGC GCA CAU
CUU G-3⬘; J006656-08, 5⬘-CCA AUA GGC UUA AUC CUG
U-3⬘) were transfected into PARP-1⫹/⫹ MEF cells by using Oligofectamine according to the manufacturer’s instructions
(Invitrogen). After 48 –72 h, the cells were further transfected
with either wild-type or mutant KLF8 constructs.
Ubiquitination Assay—PARP-1⫺/⫺ and PARP-1⫹/⫹ cells
were grown to ⬃60% density in 6-well plates. The cells were
transfected with a combination of 1.0 g of pKH3-KLF8 or
pKH3-KLF8 mutant and 1.0 g of Myc-ubiquitin. At 48 h after
transfection, cells were treated with 20 M of the proteasomal
inhibitor MG132. Then anti-HA precipitates from the cell
lysates were analyzed by Western blotting using anti-HA and
anti-Myc antibodies.
Cycloheximide (CHX) Chase Assays—PARP-1⫺/⫺ and
PARP-1⫹/⫹ cells were transfected with either plasmids or
siRNAs. At 48 h after transfection, the cells were treated with 3
M PJ-34 for 12 h, 10 mM nicotinamide for 12 h, or 0.6 g/ml
doxorubicin for 8 h. Then the cells were treated with 50 g/ml
VOLUME 286 • NUMBER 23 • JUNE 10, 2011
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FIGURE 1. KLF8 interacts with PARP-1 and is PARylated. A, identification of PARP-1 as a KLF8-interacting protein by co-IP and mass spectrometry. 293T cells
were transfected with HA-KLF8, Myc-KLF8, or control (Ctr) vectors for 24 h. Whole cell lysates were prepared for IP with anti-HA- or anti-Myc-conjugated agarose
beads. The precipitated proteins were resolved by SDS-PAGE and revealed by Coomassie Blue staining. B, PARP-1 was co-immunoprecipitated with PARylated
KLF8 in multiple cell types. 293T, T80, or MCF-10A cells were transfected with HA-KLF8 or control vector. Whole cell lysates or anti-HA precipitates (IP) were
analyzed by Western blot (IB) with anti-PARP-1, anti-HA, or anti-PAR antibody. Anti-␤-actin blotting was used as a loading control. C, KLF8 was co-immunoprecipitated with PARP-1. 293T cells were transfected with HA-KLF8, and whole cell lysate was subjected to IP with anti-PARP-1 or control IgG followed by the
indicated IB. D, endogenous KLF8 was co-immunoprecipitated with PARP-1. Hs579T breast cancer cell lysate was subjected to IP with anti-PARP-1 or control IgG
followed by anti-KLF8 IB. E, KLF8 and PARP-1 interact directly. Recombinant PARP-1 protein was pulled down with GST, GST-KLF8, or GST-KLF8-mut fusion
protein conjugated to glutathione agarose beads (top panel, Coomassie Blue staining) followed by anti-PARP-1 blotting (bottom panel).

CHX before lysates were collected at different time points and
analyzed by anti-HA Western blotting.
Chromatin Immunoprecipitation (ChIP) Assays—ChIP
assays were performed essentially as we previously described (2,
3, 6, 11, 24), using the Millipore EZ-ChIPTM kit according to the
manufacturer’s protocol with minor modifications. pKH3 vector, pKH3-KLF8, or its ZF1,2mCs mutant (KLF8-mut) was
transiently transfected into primary PARP-1⫹/⫹ or PARP-1⫺/⫺
MEF cells. Sonicated lysates prepared from 2 ⫻ 106 cells were
subjected to immunoprecipitation overnight at 4 °C using the
anti-HA, anti-PARP-1, or anti-p300 antibody or control IgGs
followed by a rotation for 1 h at 4 °C with 60 l of protein A/G
agarose beads. Primers are specific for the mouse cyclin D1
promoter to amplify the KLF8 binding region (11).
GST Pulldown Assays—Purified GST, the GST fusion with
the dN50-KLF8 (4) (GST-KLF8), or its ZF1,2mCs mutant
(GST-KLF8-mut) was coupled to glutathione-agarose beads
from Thermo Scientific for 1 h. After three washes with PBS
JUNE 10, 2011 • VOLUME 286 • NUMBER 23

buffer containing protease inhibitors, glutathione-agarosecoupled GST proteins were subsequently incubated for 2 h at
4 °C with equal amount of the recombinant PARP-1 protein
(Enzo Life Sciences, ALX-201-250-C010), washed three times,
resolved on SDS-PAGE, and followed by anti-PARP-1 blotting.

RESULTS
Identification of PARP-1 as a Novel KLF8-interacting Protein—KLF8-interacting proteins in the cells remain largely
unknown. To identify and characterize these proteins, we coupled parallel co-IP and mass spectrometry (Fig. 1A). We overexpressed HA-KLF8 or Myc-KLF8 in HEK293T cells. The
empty vector (pKH3 for HA or pHAN for Myc) transfected cells
were used as negative controls. The whole cell lysates prepared
from these transfected cells were subjected to IP with either
anti-HA or anti-Myc antibody-conjugated agarose beads. After
being resolved by SDS-PAGE, the precipitated proteins were
visualized by Coomassie Blue staining. The protein bands that
JOURNAL OF BIOLOGICAL CHEMISTRY
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were pulled down from both HA-KLF8-expressing and MycKLF8-expressing cells (Fig. 1A, lanes 2 and 3) but not from the
vector transfected cells (Fig. 1A, lanes 1 and 4) were excised for
further analysis by mass spectrometry. PARP-1 was strongly
and consistently present in the ⬃120-kDa band and thus chosen for further characterization (Fig. 1A). To investigate
whether PARP-1 modifies KLF8 protein by PARylation, we
blotted the anti-HA precipitated KLF8 protein with a specific
anti-PAR antibody. We found that the KLF8 protein was PARylated in all three cell types (Fig. 1B, row g). We confirmed that
the interaction between KLF8 and PARP-1 occurs not only in
HEK293T cells, but also in T80 and MCF10A cells that
expressed ectopic HA-KLF8 by anti-HA co-IP (Fig. 1B, rows e
and f) and anti-PARP-1 co-IP (Fig. 1C). These results indicated
that the interaction might be general in epithelial cell types. The
interaction was further verified by anti-PARP-1 co-IP of endogenous KLF8 (Fig. 1D) and GST-KLF8 pulldown of recombinant
PARP-1 protein (Fig. 1E). Inclusion of ethidium bromide in the
co-IP reaction did not affect the interaction (supplemental Fig.
2). These results clearly indicate that KLF8 directly interacts
with PARP-1 probably independent of DNA binding in a variety
of cell types and that the PARylation of KLF8 by PARP-1 may be
important in regulating KLF8 function in the cells.
KLF8 Interacts with PARP-1 through the First and Second
Zinc Finger Domains, and the Interaction Is PARylationindependent—To map the PARP-1 binding site(s) on KLF8, we
took advantage of the KLF8 truncation mutants we made previously (4) and performed similar transfection and co-IP (Fig.
2A). We found that the N-terminal truncation up to 200 amino
acid residues did not affect the interaction with PARP-1 (Fig.
2A, compare lanes 7 and 8 with lane 6). Further N-terminal
truncations were not tested as those mutants are known to mislocalize to the cytoplasm instead of nucleus (4). In contrast, the
C-terminal deletion of zinc finger (ZF) domain, particularly the
complete deletion of all three ZFs (dC82), disrupted the interaction (Fig. 2A, compare lanes 2–5 with lane 6).
Using the internal ZF deletion mutants and point mutants of
KLF8 (19) (Fig. 2, B and C) for the co-IP experiments, we determined that deletion of ZF1 resulted in partial loss of the interaction and that deletion of ZF2 almost abolished the interaction
(Fig. 2B, lanes 1 and 2). Interestingly, mutation of the DNA
contact motifs of ZF2 or both the cysteines of ZF2 reduced the
interaction to the same content as the deletion of ZF2 (Fig. 2B,
lane 5, and Fig. 2C, lane 7), whereas mutation of two histidines
(Fig. 2B, lane 6) or the individual cysteines (Fig. 2C, lanes 4 and
5) of ZF2 or any of the cysteines, histidines, or DNA contact
motifs of ZF1 (Fig. 2B, lanes 3 and 4, and Fig. 2C, lanes 2, 3, and
6) did not affect the interaction.
Anti-PAR blotting indicated that the ZF2mCs mutant had
significantly reduced levels of PARylation (Fig. 2C, row c, compare lane 7 with lane 9). Interestingly, the ZF1mCs mutant
displayed a similar degree of reduction in PARylation (Fig. 2C,
row c, compare lane 6 with lane 7), and mutation of all the
cysteines in both ZF1 and ZF2 did not cause a further reduction
of the PARylation (Fig. 2C, row c, compare lane 8 with lanes 6
and 7). The PARylation of KLF8 was totally abolished by the
PARP-1 specific inhibitors (supplemental Fig. 3A).
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FIGURE 2. KLF8 interacts with PARP-1 through its ZFs independent of the
catalytic activity of PARP-1. A, the ZF1 and ZF2 region is required for KLF8
interaction with PARP-1. HEK293T cells were transfected with the indicated
Myc-tagged KLF8 or mutants or with empty vector. The protein expression
was verified by anti-Myc IB of the whole cell lysates (supplemental Fig. 1A).
The anti-Myc IP followed by IB with either anti-Myc or anti-PARP-1 was performed as in Fig. 1B. B, the histidine residues and DNA contact motifs in ZF1 or
ZF2 are not required for KLF8 binding to PARP-1. The indicated Myc-tagged
KLF8 mutants were used for co-IP similarly as in A. The protein expression was
verified by anti-Myc IB of the whole cell lysates (supplemental Fig. 1B).
C, the cysteine residues in ZF2 are most critical for KLF8 binding to PARP-1.
The indicated HA-tagged KLF8 point mutants were used for similar co-IPs. The
protein expression was verified by anti-HA IB of the whole cell lysates (supplemental Fig. 1, C and D). PARylation of KLF8 (PAR-KLF8) was determined by
anti-PAR blotting (in row c, lane 5 represents vector-transfected cells). D, KLF8
interaction with PARP-1 does not require PARP-1 catalytic activity. PARP-1⫺/⫺
MEFs were transfected with the indicated expressing plasmids for co-IP
assays. The protein expression was verified by anti-Myc and anti-HA IB of the
whole cell lysates (supplemental Fig. 1E).

To determine whether KLF8 interaction with PARP-1
depends upon the catalytic activity of PARP-1 on modification
of KLF8, we co-expressed KLF8 and either wild-type PARP-1 or
its catalytic dead mutant E988K in the PARP-1-null MEF cells
and performed co-IP analysis (Fig. 2D). We found that like the
wild-type PARP-1, the E988K mutant remained capable of
interacting with KLF8 (Fig. 2D, row a, compare lane 4 with lane
3) despite the incapability of autoPARylation (Fig. 2D, row b,
compare lane 4 with lane 3) and PARylation of KLF8 (Fig. 2D,
row d, compare lane 4 with lane 3). Taken together, these
results suggest that KLF8 interaction with PARP-1 is mainly
through the cysteine residues in ZF2 of KLF8 independent of
VOLUME 286 • NUMBER 23 • JUNE 10, 2011
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the catalytic activity of PARP-1 and that the PARylation of
KLF8 is specifically mediated by PARP-1, which depends on
both the ZF2-mediated interaction between the two proteins
and the presence of the ZF1 cysteines in KLF8.
Interaction with PARP-1 Is Essential for the Nuclear Localization of KLF8—Next, we sought to verify the nuclear localization
of the newly generated KLF8 mutants described in Fig. 2C. We
transiently expressed these mutants in HEK293T and NIH3T3
cells and carried out immunofluorescent staining. All these
mutants were localized in the nucleus with the exception of the
PARP-1 binding-deficient mutants ZF2mCs and ZF1,2mCs,
which were localized in both the nucleus and the cytoplasm
(data not shown). This surprising finding was confirmed when
the ZF1,2mCs mutant was transiently expressed in the PARP1⫹/⫹ MEF cells and compared with the wild-type KLF8 (Fig. 3,
A and C, compare KLF8-mut and KLF8 in the PARP-1⫹/⫹ MEF
cells). Even the wild-type KLF8 was dramatically mislocalized
in the cytoplasm when PARP-1 expression in the PARP-1⫹/⫹
MEF cells was silenced by RNAi (Fig. 3A, c1–c3, and Fig. 3D,
compare siPARP-1 with siCtrl). Interestingly, treatment of the
cells with the PARP-1 inhibitor PJ-34 only resulted in a slight
KLF8 mislocalization in the cytoplasm (Fig. 3A, panels d1– d3,
and Fig. 3D, compare PJ-34 with siCtrl). This result was further
verified using the PARP-1⫺/⫺ MEF cells. In these cells, KLF8,
like the KLF8-mut, was clearly and completely mislocalized in
the cytoplasm (Fig. 3B, compare KLF8 with KLF8-mut, and Fig.
3C, compare PARP-1⫺/⫺ with PARP-1⫹/⫹ MEF cells for KLF8).
Also, this mislocalization was prevented by re-expression of
either the wild-type PARP-1 (Fig. 3B, panels c1– c3) or its catalytically dead mutant (Fig. 3B, panels d1– d3). These results
were reproduced using the freshly isolated PARP-1⫹/⫹ and
PARP-1⫺/⫺ primary MEF cells, additional PARP-1 inhibitors, and various PARP-1 siRNAs (supplemental Fig. 4, A and
B). These results suggest that KLF8 interaction with PARP-1
is required for the nuclear localization of KLF8, whereas
PARylation is dispensable.
PARP-1 Binding and PARylation Inhibit the Interaction
between KLF8 and CRM1—To test whether the KLF8 mislocalization to the cytoplasm is associated with the nuclear exporting protein CRM1-dependent nucleus-to-cytoplasm trafficking
mechanism, we treated the PARP-1⫺/⫺ MEF cells with the
CRM1 inhibitor LMB. We found that this treatment significantly reduced the cytoplasmic presence of KLF8 (Fig. 4, A and
B, compare LMB⫹ with LMB⫺). This result suggests that
KLF8 interaction with CRM1 may be critical for KLF8 cytoplasmic mislocalization in the absence of PARP-1. To test
this possibility, we re-expressed KLF8 and its mutant KLF8mut in the PARP-1⫺/⫺ MEF cells and performed co-IP analysis. As expected, we found that KLF8 and its mutant interacted with CRM1 equally (Fig. 4C, row a, lanes 2 and 3). The
CRM1 interaction with KLF8 was completely blocked by coexpression of either wild-type PARP-1 or its E988K mutant
(Fig. 4C, row a, lanes 4 and 6), whereas the CRM1 interaction
with the KLF8-mut was only slightly prevented by PARP-1
re-expression (Fig. 4C, row a, lane 5). On the other hand,
similar co-IP experiments showed that KLF8 interaction
with CRM1 was most remarkably increased in the PARP1⫹/⫹ MEF cells when PARP-1 expression was silenced (Fig.
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FIGURE 3. Interaction with PARP-1 is essential for the nuclear localization
of KLF8. A, KLF8 mislocalizes in the cytoplasm when its PARP-1 binding site is
disrupted or PARP-1 is knocked down but not when PARP-1 activity is inhibited. PARP-1⫹/⫹ MEFs were transfected with KLF8 or its PARP-1 binding-deficient mutant (KLF8-mut) individually or in combination with treatment with
PARP-1 siRNA (siPARP-1) or inhibitor (PJ-34, 3 M). GFP siRNA was used as
negative control. After 34 – 48 h, cells were analyzed by anti-HA staining of the
KLF8 proteins (green) and Hoechst staining of the nuclei (blue) followed by
fluorescent microscopy. Scale bar, 20 m. B, cytoplasmic mislocalization of
KLF8 in PARP-1⫺/⫺ MEFs can be prevented by ectopic expression of both
wild-type PARP-1 and its PARylase dead mutant (E988K). PARP-1⫺/⫺ cells
were transfected with KLF8 or KLF8-mut alone or along with PARP-1 or its
dead mutant. After 24 h, cells were analyzed by anti-HA staining of the KLF8
(green), anti-Myc staining of PARP-1, and Hoechst staining of the nuclei (blue)
followed by fluorescent microscopy. C and D, statistical analysis of data represented in A and B. The data represent the mean ⫾ S.E. of at least three
independent experiments. For each experiment, 200 cells were examined. *,
p ⬍ 0.01 for difference in nuclear localization (Nuc) only.

4D, row a, compare lane 5 with lane 2). It should be noted
that the affinity of KLF8 binding to PARP-1 and CRM1 was
reversely correlated (Fig. 4, C and D, compare row a and row
b). These results support the notion that PARP-1 maintains
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FIGURE 4. PARP-1 competes with nuclear exportin protein CRM1 to regulate KLF8 subcellular localization. A, cytoplasmic mislocalization of KLF8 in
PARP-1⫺/⫺ MEFs can be prevented by inhibiting CRM1. PARP-1⫺/⫺ MEFs were transfected with KLF8 with or without LMB (3 nM) treatment. After 24 h, the cells
were analyzed by anti-HA staining of the KLF8 (green) and Hoechst staining of the nuclei (blue) followed by fluorescent microscopy. B, statistical analysis of data
represented in A. Data represent the mean ⫾ S.E. of at least three independent experiments. For each experiment, 200 cells were examined. *, p ⬍ 0.01 for
difference in nuclear localization (Nuc) only. C, KLF8 interacts with CRM1 in PARP-1⫺/⫺ MEFs, which can be prevented by ectopic expression of PARP-1 or its
PARylase dead mutant. PARP-1⫺/⫺ MEFs were transfected with empty vector, with KLF8 or KLF8 mutant alone, or along with PARP-1 or its E988K mutant. After
24 h, whole cell lysates were prepared for anti-HA IP followed by IB with anti-PARP-1, anti-CRM1, and anti-HA. D, KLF8 interaction with CRM1 is enhanced by
PARP-1 knockdown. PARP-1⫹/⫹ MEFs were transfected for 24 h with empty vector, KLF8, or KLF8-mut with or without prior treatment with PARP-1 siRNA or GFP
siRNA as control for 48 h or PJ34 for 4 h (6 M). Whole cell lysates were prepared for IP as in C. Effective overexpression and knockdown were confirmed
(supplemental Fig. 1, F–H).

the nuclear localization of KLF8 by competing with CRM1
for KLF8 binding.
PARP-1 Is Required for the Stability of KLF8 Protein in the
Cell—Export of a nuclear protein to the cytoplasm usually
results in either the cytoplasmic destruction or the cytoplasmic
function of the protein. Assuming that the function of KLF8 is
restricted in the nucleus given that it is a transcription factor,
we first tested whether the nuclear export of KLF8 leads to its
degradation in the cytoplasm. We overexpressed KLF8 or its
mutant KLF8-mut in either the PARP-1⫹/⫹ or the PARP-1⫺/⫺
MEFs and performed CHX chase assays (Fig. 5). We found that
the half-life of KLF8 was reduced from ⬃16 h in the PARP-1⫹/⫹
MEFs to only ⬃4 h in the PARP-1⫺/⫺ MEFs (Fig. 5, A and C).
The KLF8-mut had an even shorter half-life of ⬃4 h in the
PARP-1⫹/⫹ cells and was further shortened to only ⬃1 h in the
PARP-1⫺/⫺ cells (Fig. 5, B and C). In the PARP-1⫹/⫹ cells,
the half-life of KLF8 was reduced to 4 – 8 h when PARP-1
expression was silenced or its activity was inhibited (Fig. 5, D
and E). Based on these results, we concluded that both PARP-1
interaction and PARylation are important for maintaining the
stability of KLF8 protein in the cell.
The Interaction with and PARylation by PARP-1 Affect the
Ubiquitination of KLF8—Ubiquitination-mediated proteasomal degradation of proteins is a most common mechanism that
regulates protein stability. To determine whether this mechanism
regulates KLF8 protein turnover in the cell, we co-expressed KLF8
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or KLF8-mut and ubiquitin in the MEFs, treated the cells with the
proteasome inhibitor MG132, and examined the ubiquitination
status of KLF8 protein by co-IP analysis (Fig. 6A). We found that
the levels of ubiquitinated KLF8 were significantly higher in the
PARP-1⫺/⫺ MEFs than the PARP-1⫹/⫹ MEFs (Fig. 6A, compare
lane 2 with lane 7) and that the KLF8-mut was more ubiquitinated
than KLF8 in the presence of PARP-1 (Fig. 6A, compare lane 10
with lane 7) but not in the absence of PARP-1 (Fig. 6A, compare
lane 5 with lane 2). These results suggest that PARP-1 protects
KLF8 from ubiquitination.
To test whether nuclear export is required for the ubiquitination of KLF8, we treated the PARP-1⫺/⫺ MEF cells with LMB
and performed a similar ubiquitination analysis (Fig. 6B). We
found that the ubiquitination of KLF8 was strongly inhibited by
LMB (Fig. 6B, compare lane 3 with lane 2). This result suggests
that loss of PARP-1 interaction results in KLF8 ubiquitination
primarily subsequent to its export to the cytoplasm.
To determine whether the PARylation of KLF8 affects its
ubiquitination, we examined the ubiquitination status of
KLF8 in the PARP-1⫹/⫹ MEFs in the presence of the PARP-1
inhibitor PJ-34 (Fig. 6C). We found that the levels of ubiquitinated KLF8 were significantly increased by the PJ-34 treatment
(Fig. 6C, compare lane 2 with lane 3). In a separate project, we
unexpectedly found that doxorubicin treatment increased
the catalytic activity of PARP-1 (data not shown). Taking this
advantage, we enhanced the levels of PARylated KLF8 in the
VOLUME 286 • NUMBER 23 • JUNE 10, 2011
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FIGURE 5. PARP-1 is required for stabilizing KLF8 protein in the cell. A–C,
KLF8 protein has a shorter half-life in PARP-1⫺/⫺ MEFs than in PARP-1⫹/⫹ MEFs.
PARP-1⫹/⫹ or PARP-1⫺/⫺ MEFs were transfected with KLF8 (A) or KLF8-mut (B) for
36 h and then treated with CHX (50 g/ml) for the indicated periods of time.
Whole cell lysates were prepared for anti-HA and anti-␤-actin IB, and relative
intensity of KLF8 protein (K) in the blots was graphed (C). D and E, the half-life of
KLF8 protein is shortened when PARP-1 expression is knocked down or activity is
inhibited. PARP-1⫹/⫹ MEFs were transfected for 36 h with KLF8 after the prior
transfection with the indicated siRNAs for 48 h or treatment with PJ-34 (3 M,
12 h). After being chased with CHX treatment for the indicated periods of time,
whole cell lysates were prepared for anti-HA and anti-␤-actin IB (D), and relative
intensity of KLF8 protein in the blots was graphed (E).

PARP-1⫹/⫹ MEFs using doxorubicin treatment and found that
this treatment protected KLF8 from ubiquitination (Fig. 6C,
compare lane 5 with lane 3). These results indicated an inverse
correlation between the PARylation and ubiquitination of
KLF8 and suggested an opposing cross-talk between these
potentially important post-translational modification of KLF8.
Interaction with and PARylation by PARP-1 Are Required
for the Transcriptional Activity of KLF8—KLF8 was previously shown as a transcription activator of cyclin D1 gene
promoter (1, 11). To determine the effect of PARP-1 on the
transcriptional activity of KLF8, we performed cyclin D1
promoter luciferase reporter assays (Fig. 7). We found that
the activation of cyclin D1 promoter by KLF8 was dramatically reduced when PARP-1 was deleted (Fig. 7A, left panel,
compare column 2 with column 8) or catalytically inhibited
(Fig. 7A, left panel, compare columns 10 and 12 with column
8). This reduction was well correlated with the levels of PARylated
KLF8 in the cells (Fig. 7A, right panel, row g, compare lanes 3 and 4
with lane 2). Similarly, the promoter activation was attenuated by
disruption of KLF8 interaction with PARP-1 (Fig. 7B, left panel,
compare column 3 with column 2) or by silencing PARP-1 expression (Fig. 7B, left panel, compare column 5 with column 2) in the
JUNE 10, 2011 • VOLUME 286 • NUMBER 23

FIGURE 6. KLF8 can be ubiquitinated, which can be inhibited by PARP-1.
A, KLF8 ubiquitination level is higher in PARP-1⫺/⫺ MEFs than in PARP-1⫹/⫹
MEFs. PARP-1⫹/⫹ or PARP-1⫺/⫺ MEFs were co-transfected with HA-KLF8 or its
KLF8-mut mutant and Myc-ubiquitin (Myc-Ub) for 48 h. The cells were then
treated with MG132 (20 M, 8 h). Whole cell lysates were prepared for IP with
anti-HA followed by IB with anti-Myc or anti-HA. B, KLF8 ubiquitination (Ub) is
prevented by LMB treatment. PARP-1⫺/⫺ MEFs were transfected, treated, and
analyzed as in A except for the treatment with LMB (3 nM) during the last 10 h.
C, KLF8 ubiquitination level is inversely correlated with its PARylation level
and PARP-1 catalytic activity in the cell. PARP-1⫹/⫹ MEFs were transfected,
treated, and analyzed as in A except for the treatment with PJ-34 (3 M) or
doxorubicin (Dox) during the last 10 h.

PARP-1⫹/⫹ MEFs. Importantly, the activation of cyclin D1
promoter by KLF8 in the cells was consistent with the change
in cyclin D1 protein levels (Fig. 7B, right panel, row b, compare lanes 3, 5, and 6 with lane 2). Conversely, re-expression
of PARP-1 (but not its E988K mutant) in the PARP-1⫺/⫺
MEFs restored the ability of KLF8 (but not its KLF8-mut
mutant) to activate the cyclin D1 promoter (Fig. 7C, left
panel, compare column 6 with columns 4, 7, and 8) and promote cyclin D1 protein expression in the cells (Fig. 7C, right
panel, row b, compare lane 4 with lanes 2, 5, and 6). InterJOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 7. KLF8 transcriptional activity depends partially on interaction with and modification by PARP-1. A, KLF8 activates cyclin D1 promoter more
potently in the presence than in the absence of PARP-1 activity. PARP-1⫺/⫺ or PARP-1⫹/⫹ MEFs were transfected with KLF8 or control vector along with cyclin
D1 promoter reporter for 24 h with or without further treatment with PJ34 (3 M) or nicotinamide (NAM, 10 mM) for an additional 12 h. Luciferase assays were
performed as described under “Experimental Procedures” (left panel). KLF8 interaction with and PARylation by PARP-1 in the PARP-1⫹/⫹ MEFs were confirmed
by anti-HA IP followed by IB with anti-PARP-1 and anti-PAR (right panel). B, KLF8 activation of cyclin D1 transcription requires PARP-1 interaction and activity.
PARP-1⫹/⫹ MEFs were transfected with PARP-1 siRNA or GFP siRNA for 48 h followed by transfection with KLF8, KLF8-mut, or control vector along with the
cyclin D1 promoter reporter. Luciferase assays (left panel) and IB for indicated proteins (right panel) were performed as in A. C, up-regulation of cyclin D1
expression by KLF8 in PARP-1⫺/⫺ MEFs is enhanced by ectopic expression of PARP-1 in an interaction- and PARylation-dependent manner. PARP-1⫺/⫺ MEFs
were co-transfected with KLF8, KLF8-mut, or control vector and either PARP-1 or its E988K mutant for 24 h. Luciferase assays (left panel) and IB for indicated
proteins (right panel) were performed as in B. Data in all the graphs represent the mean ⫾ S.E. of at least three independent duplicate experiments. *, p ⬍ 0.01.

estingly, ChIP assays did not detect PARP-1 protein at the
cyclin D1 promoter region where both KLF8 and p300 bind,
although this promoter binding by KLF8 and p300 largely
depends upon PARP-1 activity (supplemental Fig. 5). These
results clearly indicated that PARP-1 plays a critical role in
the regulation of KLF8 transcriptional activity through
interaction with and PARylation of KLF8 in the nucleus.
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DISCUSSION
Both KLF8 and PARP-1 play an important role associated
with human diseases including cancer. Our novel findings that
PARP-1 binds KLF8 in various cell types and regulates KLF8 in
various aspects shed new light on both KLF8 and PARP-1
research with potentially significant clinical impact. We propose that KLF8 needs to stay in the nucleus to regulate target
VOLUME 286 • NUMBER 23 • JUNE 10, 2011
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gene transcription and possibly PARP-1-associated nuclear
events. The nuclear localization of KLF8 requires its interaction
with PARP-1 in the nucleus, which prevents KLF8 from being
exported to the cytoplasm and subsequent degradation.
The fact that PARP-1 interaction with KLF8 prevents the
nuclear exportin CRM1 from binding to KLF8 suggests that
PARP-1 serves as a nuclear retention factor of KLF8. In agreement with this work, other groups have recently demonstrated
a role for PARP-1 to regulate the nuclear localization of p65
NF-B and p53 (22, 25). We have previously identified two
nuclear localization signals for KLF8, one of which is located
within the ZF DNA binding domain (4). That work also demonstrated that both nuclear importin-␤ and CRM1 are involved
in the regulation of KLF8 nuclear localization (4). It is plausible
to consider that the nuclear localization signal in the ZF domain
serves as a platform for PARP-1 to keep KLF8 in the nucleus
after KLF8 is carried into the nucleus by the nuclear importin.
Because the ZF DNA binding domain is required for KLF8
interaction with both importin-␤ and PARP-1, it is also possible
that PARP-1 relays KLF8 from the importin and helps send
KLF8 to promoter DNA of target genes in the nucleus. PARP-1
has been suggested to function as a bona fide transcriptional
co-activator, as in the case of PARP-1 regulation of NFB-mediated transcription (26). In contrast, our results show that
PARP-1 does not stay together with KLF8 at the promoter of
cyclin D1, suggesting that PARP-1 likely works as a messenger
to pass KLF8 from the nuclear importin to another co-activator,
such as the histone acetyltransferases p300 and p300/CBP-associated factor transcription (11), at the promoter and lets the
latter do the job of transcriptional co-activation. Indeed, we
have shown that the histone acetyltransferase-mediated acetylation on both histones (11) and KLF8 protein (9) is required for
the activation of the cyclin D1 promoter, and the binding to the
cyclin D1 promoter by both KLF8 and p300 heavily depends
upon PARP-1 activity. These results suggest an interesting
notion that PARP-1 promotes an exchange of a co-repressor
complex with a co-activator complex at the target promoter in
a dynamic manner (14). Consistently with this notion, our
result shows that only a fraction of KLF8 protein molecules
interacts with PARP-1 (see supplemental Fig. 3B). Therefore,
PARP-1 interaction with KLF8 may have multifold significance.
First, it prevents CRM1-dependent nuclear export of KLF8.
Second, it helps the PARylation of KLF8, which in turn helps
formation of a co-activator complex at a KLF8 target promoter.
Third, it helps to temporarily put KLF8 into sleep when the cell
needs KLF8 to be away from its target gene promoters, or
fourth, it may help switch KLF8 from one group to another
group of target gene promoters to meet the cellular requirement. Nevertheless, constitutive PARP-1 interaction could
restrict the ability of KLF8 to regulate its target gene expression,
as in the case of PARP-1 regulation of Sp1 (28).
Nevertheless, all the possibilities described above have
pointed to a conclusion that in the nucleus, KLF8 is localized to
at least two compartments, at the target gene promoters
together with its transcriptional co-regulators or away from the
promoter and likely together with PARP-1. This subnuclear
compartmentation dictates where and how KLF8 protein is
modified and possibly where and how KLF8 functions in the
JUNE 10, 2011 • VOLUME 286 • NUMBER 23

nucleus. It will be interesting to test whether KLF8 is differentially modified post-translationally by the histone acetyltransferase-mediated acetylation and PARP-1-mediated
PARylation. We have recently demonstrated that KLF8 is
also modified by sumoylation in the nucleus and that this
modification delimits the ability of KLF8 to activate transcription and to promote cell proliferation (3) and is counteracted by the acetylation of KLF8 (9). Whether or not KLF8
sumoylation and PARylation are also mutually associated or
regulated and take place at the same subnuclear compartment is not known but a very interesting question to address.
Does KLF8 play any active role in this compartment containing PARP-1, and how is this role affected by these post-translational modification statuses? Experiments are in progress to
answer these interesting questions.
In addition to KLF8, ubiquitination-mediated proteasomal
degradation has been reported to regulate other KLF family
members including KLF5 (29, 30), KLF2 (31), and KLF10 (32).
One KLF protein can be targeted by more than one ubiquitin E3
ligase, such as the homologous to the E6-AP carboxyl terminus
domain E3-ubiquitin ligase WWP1 (29) and the F-box ubiquitin E3 ligase Fbw7 (30, 33). On the other hand, one ubiquitin E3
ligase such as WWP1 can target more than one KLF protein for
proteasomal degradation (29, 31). The E3 ligase that targets
KLF8 for ubiquitination and subsequent proteasomal degradation is currently unknown. WWP1 or Fbw7 does not appear to
be the one as there is not an evident potential targeting site for
either of the E3 ligases in KLF8, suggesting that the ubiquitination of KLF8 is likely mediated by a different E3 ligase still to be
identified. It appears likely that the ubiquitination of KLF8
takes place primarily in the cytoplasm given that LMB treatment prevents it in the PARP-1⫺/⫺ MEF cells. Because E3 ligases
usually target the activation domains of transcriptional factors and
frequently involve phosphorylation of the target protein, it will be
interesting to test whether KLF8 is targeted by any E3 ligase at its
activation domain (11) and whether any phosphorylation events
within this domain are involved.
The fact that interaction between KLF8 and PARP-1 takes
place in several different types of cells suggests a general importance of this regulation. In addition, consistent with our results,
another KLF family member KLF5 has recently been reported
to interact with PARP-1 in a ZF-dependent manner (34).
Because the ZF domains are well conserved among the KLF
family proteins, the PARP-1-mediated regulatory mechanism
identified in this work could apply to other KLF family proteins
as well. Like KLF8, several other KLF family members including
KLF4, KLF5, KLF6, KLF8, KLF9, KLF10, KLF11, and KLF12 are
involved in cancer pathobiology (27, 35). PARP-1 has long been
considered as a molecular target to enhance anti-cancer therapeutic efficiency (12, 15–18). Therefore, our novel results
presented in this work highlight the clinical significance of cotargeting PARP-1 and KLF8 (or other potential PARP-1-interacting KLFs) as a novel anti-cancer therapeutic strategy.
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